patiromer

01/01/2022 - "Patiromer used for the treatment of CKD reduces hyperkalemia recurrence leading to improved patient care. "
01/01/2017 - "Patiromer and ZS9 have improved upon the age-old standard SPS for the treatment of hyperkalemia. "
11/12/2023 - "This study represents the first head-to-head comparison of patiromer and SZC in the setting of acute hyperkalemia. "
04/11/2023 - "Efficacy and Safety of Patiromer for Chronic Hyperkalemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials."
01/01/2020 - "This is the first study showing that patiromer may have a role in the acute management of hyperkalemia; however, more rigorous studies are needed."

06/07/2023 - "The authors conducted a systematic search in Pubmed, Embase, Web of Science, and Cochrane Library for randomized controlled trials investigating the efficacy and safety of patiromer in heart failure patients from inception to 31 January 2023 and updated on 25 March 2023. "
06/07/2023 - "The Efficacy and Safety of Patiromer for Heart Failure Patients: A Systematic Review and Meta-Analysis."
12/01/2022 - "Patiromer for hyperkalaemia in heart failure."
01/01/2022 - "Whether the initiation of SZC is associated with an increased risk of hospitalization for heart failure (HHF) compared with patiromer in routine practice remains unknown. "
09/21/2020 - "Patiromer and medication optimisation in heart failure with reduced ejection fraction: a Swiss perspective."

03/03/2023 - "This was a real-world observational study of US veterans with chronic kidney disease and a baseline K+ ≥ 5.1 mEq/L, initiated on patiromer between January 1, 2016, and February 28, 2021. "
01/01/2023 - "Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN."
01/01/2023 - "Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany."
12/01/2022 - "METHODS: All veterans who initiated patiromer between January 1, 2016, and February 28, 2021, with chronic kidney disease and dispensed SPS during the 3 months preceding patiromer were included. "
09/01/2022 - "Patients remained taking patiromer treatment for an average of 7.7 months, with treatment associated with reductions in the overall clinical event incidence and a delay in chronic kidney disease progression. "

01/01/2023 - "The phase 2, open-label AMETHYST-DN trial (NCT01371747) randomized 304 adults with CKD on RAASi, T2DM, hyperkalaemia (serum potassium [sK+] >5.0 mEq/L), and hypertension to receive patiromer, 8.4-33.6 g/day for 12 months. "
08/01/2020 - "Patiromer plus spironolactone in resistant hypertension and CKD."
07/01/2016 - "Future research questions that should be evaluated are: the role of patiromer in treating hyperkalemia and the potential to thereby allow the optimal management of resistant hypertension and the use of high dose MRAs in patients with acute decompensated heart failure. "
01/01/2017 - "This post-hoc analysis of OPAL-HK examined the effectiveness and safety of patiromer in reducing serum K in hyperkalemic CKD patients on RAASi, with hypertension, receiving diuretic therapy versus those not on diuretics. "
10/26/2019 - "In patients with resistant hypertension and chronic kidney disease, patiromer enabled more patients to continue treatment with spironolactone with less hyperkalaemia. "

01/01/2018 - "Patients with Type 2 diabetes, CKD, and HK [baseline serum potassium >5.0-5.5 mmol/L (mild) or >5.5-<6.0 mmol/L (moderate)], with or without HF (New York Heart Association Class I and II, by investigator judgement), on ACE-I/ARB, were randomized to patiromer 8.4-33.6 g to start, divided twice daily. "
07/14/2015 - "Phase 2, multicenter, open-label, dose-ranging, randomized clinical trial (AMETHYST-DN), conducted at 48 sites in Europe from June 2011 to June 2013 evaluating patiromer in 306 outpatients with type 2 diabetes (estimated glomerular filtration rate, 15 to <60 mL/min/1.73 m2 and serum potassium level >5.0 mEq/L). "
01/01/2023 - "We assessed the potassium binder, patiromer, on continuation of RAASi therapy in hyperkalaemic patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) in the AMETHYST-DN trial, propensity score-matched to a real-world cohort not receiving patiromer (Salford Kidney Study). "
01/01/2016 - "The materials discussed three main clinical trials (PEARL-HF, OPAL-HK and AMETHYST-DN) and examined the safety and efficacy of patiromer in patients with hyperkalemia or at risk for hyperkalemia who have chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), hypertension and/or heart failure (HF) while receiving renin-angiotensin-aldosterone system inhibitors (RAASis). "
05/01/2021 - "This post hoc subgroup analysis aimed to evaluate the effectiveness of patiromer, a sodium-free nonabsorbed polymer, in lowering serum potassium levels in older patients receiving a renin-angiotensin-aldosterone system inhibitor with chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and hypertension. "